UCB gets FDA approval for Bimzelx for hidradenitis suppurativa
UCB has received FDA approval for its drug Bimzelx for the treatment of moderate-to-severe hidradenitis suppurativa, or HS.
Medscape3d
FDA Approves Bimekizumab for Adults With Hidradenitis Suppurativa
The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...
emjreviews.com2d
FDA greenlights UCB’s IL-17 inhibitor for HS
The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...
环球老虎财经专栏 on MSN2d
三生国健重组抗IL-17A人源化单克隆抗体注射液608上市申请获得国家药品监督管理局受理
三生国健(证券代码：688336.SH)宣布，公司于近日向国家药品监督管理局递交的重组抗IL-17A人源化单克隆抗体注射液（608）上市申请已于11月18日获得受理，用于治疗成人中重度斑块状银屑病。
Business Insider1d
Protagonist Therapeutics price target raised to $67 from $51 at BTIG
The company’s PN-881 is the only oral IL-17A/F inhibitor, and it achieves potency comparable to bimekizumab in pre-clinical assays, the analyst tells investors in a research note. Eli Lilly’s (LLY) ...
腾讯网3d
持续缓解近1年！FDA批准潜在重磅疗法
▎药明康德内容团队编辑优时比（UCB）今天宣布，美国FDA已批准Bimzelx（bimekizumab）用于治疗中度至重度化脓性汗腺炎（HS）成人患者。根据新闻稿，Bimzelx是可同时选择性抑制白介素17A（IL-17A）和白介素17F（IL-17 ...